Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

ISSN： 1530-7905

Source： Cardiovascular Toxicology, Vol.7, Iss.2, 2007-06, pp. : 140-144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage

By Hasinoff Brian

Cardiovascular Toxicology, Vol. 2, Iss. 2, 2002-06 ,pp. : 111-118

Humana Press, Inc

Access to resources Recommend Favorite

A double-headed pro-drug that overcomes chloroquine resistance

By Ginsburg H.

Trends in Parasitology, Vol. 18, Iss. 3, 2002-03 ,pp. : 103-103

Elsevier

Access to resources Recommend Favorite

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

By Hasinoff Brian Schnabl Kareena Marusak Rosemary Patel Daywin Huebner Erwin

Cardiovascular Toxicology, Vol. 3, Iss. 2, 2003-06 ,pp. : 89-99

Humana Press, Inc

Access to resources Recommend Favorite

How Medicare Works

By Friedland Robert

Generations, Vol. 29, Iss. 1, 2005-04 ,pp. : 30-34

American Society on Aging

Access to resources Recommend Favorite

How Medicaid Works

By Friedland Robert

Generations, Vol. 29, Iss. 1, 2005-04 ,pp. : 35-38

American Society on Aging

Access to resources Recommend Favorite